US-based biopharmaceutical firm Dynavax Technologies has regained full rights to DV1179, an investigational bi-functional inhibitor of toll-like receptors (TLR) 7 and 9.
The move follows the expiration of the Research and Development (R&D) collaboration and licence deal with GSK originally executed in 2008.
Currently, Dynavax has global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications.
As part of the deal, Dynavax carried out a Phase I trial of DV1179 to evaluate its safety and tolerability in healthy volunteers followed by a Phase Ib/IIa trial of safety and pharmacodynamics in patients with active systemic lupus erythematosus (SLE).
In the SLE trial, doses of up to 60mg/week for eight weeks were well tolerated and the most common adverse events observed were injection site reactions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
The company said that DV1179 failed to meet the pharmacodynamic endpoints related to reduction in interferon alpha-regulated genes in this trial.
After completion of the Phase Ib/IIa trial, GSK declined to exercise its option to licence DV1179.
The nonclinical data suggests that DV1179 may have utility in a range of other indications and Dynavax is actively evaluating opportunities to further develop this well-characterised therapeutic product candidate.
The company said that promising data have been generated in animal models of sterile inflammation, suggesting potential use of TLR 7 and 9 inhibitors, such as DV1179, in treatment of conditions including autoimmune pancreatitis and nonalcoholic steatohepatitis (NASH).
The company is also evaluating the potential of DV1179 in autoimmune diseases with localised rather than diffuse systemic manifestations, such as scleroderma and dermatomyositis.
